Edesa Biotech enters $5M securities purchase agreement with CEO; $1.54M immediate investment

Edesa Biotech, Inc.

CEO-affiliated entity invests $1,540,819 for 150 Series A-1 Preferred Shares ($10K stated value) and warrants at $3.445 conversion/exercise price.
Preferred shares convertible into 435,414 common shares; warrants cover 326,560 common shares (75% of conversion shares).
Up to $5M total investment possible; purchases over $2M require shareholder approval under Canadian law.
$10M revolving credit facility with same entity terminated; no funds drawn and no termination penalties.
Securities issued in private placement exempt from registration; subject to Canadian hold periods.

item 1.01 item 5.03 item 1.02 item 2.03 item 3.02 item 3.03 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.